IFNG and non-small cell lung carcinoma: Enhanced IFNγ gene signature (IFNγ, CD274, LAG3, CXCL9) is associated with higher overall response rates and longer median progression-free survival among metastasized non-small cell lung carcinoma, urothelial cancer or melanoma patients receiving PD-1 inhibitors or anti-PD-L1 antibodies [14, 15].